node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
ADCYAP1 | ADM | ENSP00000411658 | ENSP00000278175 | adenylate cyclase activating polypeptide 1 (pituitary); Binding to its receptor activates G proteins and stimulates adenylate cyclase in pituitary cells | adrenomedullin; AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels | 0.903 |
ADCYAP1 | ADM2 | ENSP00000411658 | ENSP00000379086 | adenylate cyclase activating polypeptide 1 (pituitary); Binding to its receptor activates G proteins and stimulates adenylate cyclase in pituitary cells | adrenomedullin 2; IMDL and IMDS may play a role as physiological regulators of gastrointestinal, cardiovascular bioactivities mediated by the CALCRL/RAMPs receptor complexes. Activates the cAMP-dependent pathway | 0.900 |
ADCYAP1 | CALCB | ENSP00000411658 | ENSP00000346017 | adenylate cyclase activating polypeptide 1 (pituitary); Binding to its receptor activates G proteins and stimulates adenylate cyclase in pituitary cells | calcitonin-related polypeptide beta; CGRP induces vasodilation. It dilates a variety of vessels including the coronary, cerebral and systemic vasculature. Its abundance in the CNS also points toward a neurotransmitter or neuromodulator role | 0.954 |
ADCYAP1 | CALCR | ENSP00000411658 | ENSP00000352561 | adenylate cyclase activating polypeptide 1 (pituitary); Binding to its receptor activates G proteins and stimulates adenylate cyclase in pituitary cells | calcitonin receptor; This is a receptor for calcitonin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The calcitonin receptor is thought to couple to the heterotrimeric guanosine triphosphate-binding protein that is sensitive to cholera toxin | 0.906 |
ADCYAP1 | IAPP | ENSP00000411658 | ENSP00000240652 | adenylate cyclase activating polypeptide 1 (pituitary); Binding to its receptor activates G proteins and stimulates adenylate cyclase in pituitary cells | islet amyloid polypeptide; Selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, while not affecting adipocyte glucose metabolism | 0.913 |
ADCYAP1 | NPS | ENSP00000411658 | ENSP00000381105 | adenylate cyclase activating polypeptide 1 (pituitary); Binding to its receptor activates G proteins and stimulates adenylate cyclase in pituitary cells | neuropeptide S; Modulates arousal and anxiety. May play an important anorexigenic role. Binds to its receptor NPSR1 with nanomolar affinity to increase intracellular calcium concentrations (By similarity) | 0.935 |
ADCYAP1 | SCT | ENSP00000411658 | ENSP00000176195 | adenylate cyclase activating polypeptide 1 (pituitary); Binding to its receptor activates G proteins and stimulates adenylate cyclase in pituitary cells | secretin; Stimulates formation of NaHCO(3)-rich pancreatic juice and secretion of NaHCO(3)-rich bile and inhibits HCl production by the stomach | 0.962 |
ADCYAP1 | VIP | ENSP00000411658 | ENSP00000356213 | adenylate cyclase activating polypeptide 1 (pituitary); Binding to its receptor activates G proteins and stimulates adenylate cyclase in pituitary cells | vasoactive intestinal peptide; VIP causes vasodilation, lowers arterial blood pressure, stimulates myocardial contractility, increases glycogenolysis and relaxes the smooth muscle of trachea, stomach and gall bladder | 0.913 |
ADM | ADCYAP1 | ENSP00000278175 | ENSP00000411658 | adrenomedullin; AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels | adenylate cyclase activating polypeptide 1 (pituitary); Binding to its receptor activates G proteins and stimulates adenylate cyclase in pituitary cells | 0.903 |
ADM | ADM2 | ENSP00000278175 | ENSP00000379086 | adrenomedullin; AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels | adrenomedullin 2; IMDL and IMDS may play a role as physiological regulators of gastrointestinal, cardiovascular bioactivities mediated by the CALCRL/RAMPs receptor complexes. Activates the cAMP-dependent pathway | 0.971 |
ADM | CALCB | ENSP00000278175 | ENSP00000346017 | adrenomedullin; AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels | calcitonin-related polypeptide beta; CGRP induces vasodilation. It dilates a variety of vessels including the coronary, cerebral and systemic vasculature. Its abundance in the CNS also points toward a neurotransmitter or neuromodulator role | 0.974 |
ADM | CALCR | ENSP00000278175 | ENSP00000352561 | adrenomedullin; AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels | calcitonin receptor; This is a receptor for calcitonin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The calcitonin receptor is thought to couple to the heterotrimeric guanosine triphosphate-binding protein that is sensitive to cholera toxin | 0.967 |
ADM | CALCRL | ENSP00000278175 | ENSP00000376177 | adrenomedullin; AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels | calcitonin receptor-like; Receptor for calcitonin-gene-related peptide (CGRP) together with RAMP1 and receptor for adrenomedullin together with RAMP3 (By similarity). Receptor for adrenomedullin together with RAMP2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase | 0.974 |
ADM | IAPP | ENSP00000278175 | ENSP00000240652 | adrenomedullin; AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels | islet amyloid polypeptide; Selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, while not affecting adipocyte glucose metabolism | 0.973 |
ADM | NPS | ENSP00000278175 | ENSP00000381105 | adrenomedullin; AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels | neuropeptide S; Modulates arousal and anxiety. May play an important anorexigenic role. Binds to its receptor NPSR1 with nanomolar affinity to increase intracellular calcium concentrations (By similarity) | 0.956 |
ADM | RAMP1 | ENSP00000278175 | ENSP00000254661 | adrenomedullin; AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels | receptor (G protein-coupled) activity modifying protein 1; Transports the calcitonin gene-related peptide type 1 receptor (CALCRL) to the plasma membrane. Acts as a receptor for calcitonin-gene-related peptide (CGRP) together with CALCRL | 0.754 |
ADM | SCT | ENSP00000278175 | ENSP00000176195 | adrenomedullin; AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels | secretin; Stimulates formation of NaHCO(3)-rich pancreatic juice and secretion of NaHCO(3)-rich bile and inhibits HCl production by the stomach | 0.910 |
ADM | VIP | ENSP00000278175 | ENSP00000356213 | adrenomedullin; AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels | vasoactive intestinal peptide; VIP causes vasodilation, lowers arterial blood pressure, stimulates myocardial contractility, increases glycogenolysis and relaxes the smooth muscle of trachea, stomach and gall bladder | 0.948 |
ADM2 | ADCYAP1 | ENSP00000379086 | ENSP00000411658 | adrenomedullin 2; IMDL and IMDS may play a role as physiological regulators of gastrointestinal, cardiovascular bioactivities mediated by the CALCRL/RAMPs receptor complexes. Activates the cAMP-dependent pathway | adenylate cyclase activating polypeptide 1 (pituitary); Binding to its receptor activates G proteins and stimulates adenylate cyclase in pituitary cells | 0.900 |
ADM2 | ADM | ENSP00000379086 | ENSP00000278175 | adrenomedullin 2; IMDL and IMDS may play a role as physiological regulators of gastrointestinal, cardiovascular bioactivities mediated by the CALCRL/RAMPs receptor complexes. Activates the cAMP-dependent pathway | adrenomedullin; AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels | 0.971 |